April 26, 2018 09:35 AM EDT
Financing

Amid hot IPO sea­son, Mereo drops Nas­daq plans cit­ing 'chal­leng­ing' mar­ket con­di­tions

Brittany Meiling

Mereo Bio­Phar­ma, a Lon­don biotech de­vel­op­ing a pipeline of as­sets it snagged from Big Phar­ma shelves, has yanked its IPO ap­pli­ca­tion to go pub­lic in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times